This publication includes existing experiences, lessons learned, challenges and future developments in the production of Ac-225 radiopharmaceuticals for Targeted Alpha Therapy (TAT). This publication ...

Under the terms of the agreement, ITM will supply its therapeutic medical radioisotope, Ac-225, produced by Actineer TM Inc. (Actineer), the joint venture between ITM and Canadian Nuclear Laboratories ...

As anticipated, we have seen robust tumor control and ATNM-400 has shown to be well tolerated in preclinical studies, which we believe is due to the precise and potent cell-killing of Ac-225.